uniQure N.V. (QURE) is a Healthcare stock trading at $46.35 (as of 2026-06-18), with a market capitalization of $1.80B and a trailing P/E of -13.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
uniQure N.V. is a gene-therapy company developing treatment candidates for genetic and other diseases. Its pipeline includes Etranacogene dezaparvovec (AMT-061) in a Phase III trial for hemophilia B and AMT-130 in Phase I/II for Huntington’s disease, among other programs for additional neurological and related indications.